Study of Sacituzumab Govitecan in Chinese Patients With Metastatic Triple-negative Breast Cancer Who Received at Least Two Prior Treatments
A phase 2 trial of Sacituzumab govitecan in triple-negative breast cancer, run by Gilead Sciences, active and no longer recruiting.
Overview
Study of Sacituzumab Govitecan in Chinese Patients With Metastatic Triple-negative Breast Cancer Who Received at Least Two Prior Treatments is a phase 2 interventional study registered as NCT04454437 by Gilead Sciences, with 80 participants enrolled, started 2020-10-23 and due to reach its primary completion in 2021-08-06. Interventions recorded: Sacituzumab Govitecan-hziy.
Similar pages
not linked directly; found by shared links- TrialA Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer
Shares Gilead Sciences (incl. Kite), Sacituzumab govitecan, Triple-negative breast cancer (TNBC) and the tag pipeline.
- TrialStudy of Sacituzumab Govitecan (SG) in Japanese Participants With Advanced Solid Tumors
Shares Gilead Sciences (incl. Kite), Sacituzumab govitecan, Triple-negative breast cancer (TNBC) and the tag pipeline.
- TrialStudy of Sacituzumab Govitecan in Participants With Metastatic Solid Tumors
Shares Gilead Sciences (incl. Kite), Sacituzumab govitecan and the tag pipeline.
- TrialStudy of Sacituzumab Govitecan in Patients With Solid Tumor
Shares Gilead Sciences (incl. Kite), Sacituzumab govitecan and the tag pipeline.
- TrialStudy of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy
Shares Gilead Sciences (incl. Kite), Sacituzumab govitecan and the tag pipeline.
- TrialStudy of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)
Shares Gilead Sciences (incl. Kite), Sacituzumab govitecan and the tag pipeline.
- TrialAsian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)
Shares Gilead Sciences (incl. Kite), Sacituzumab govitecan and the tag pipeline.
- TrialProAgio in Combination With Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer
Shares Triple-negative breast cancer (TNBC) and the tag pipeline.